KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.Br J OphthalmolPMID 34656987PMC99857462023-Mar0.98未发现恶性肿瘤人群证据。待处理
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.Prostate Cancer Prostatic DisPMID 35790787无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.AllergyPMID 35822924无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.Am J Kidney DisPMID 36058429无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.Clin Exp RheumatolPMID 36062743无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.Arthritis RheumatolPMID 36066501无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study.Prostate Cancer Prostatic DisPMID 36097167无 PMCID2023-Mar0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.J Thorac Cardiovasc SurgPMID 36137841无 PMCID2023-Mar0.93干预为非药物单独策略,未满足药物干预要求。待处理
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.Prostate Cancer Prostatic DisPMID 36209239无 PMCID2023-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis.J DermatolPMID 36353762无 PMCID2023-Mar0.90The study is a Phase III randomized trial with a drug intervention (amenamevir) and a primary time-to-event endpoint (time to healing). However, it is not an oncology study; it evaluates a treatment for recurrent herpes labialis, a non-malignant condition.待处理
Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.Lancet Infect DisPMID 36354034PMC99468392023-Mar0.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.Cancer SciPMID 36369901PMC99860932023-Mar1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.Am J Obstet GynecolPMID 36370871无 PMCID2023-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes MetabPMID 36433709无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of twice-daily tramadol hydrochloride bilayer sustained-release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double-blind, placebo-controlled, treatment-withdrawal study.Pain PractPMID 36478501无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.Clin Colorectal CancerPMID 36503738无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.Ann OncolPMID 36535565无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.Ann OncolPMID 36535566无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.Clin Colorectal CancerPMID 36564280无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.Am J HematolPMID 36588387无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.Gynecol OncolPMID 36608382PMC100233592023-Mar0.85The record describes a Phase III randomized trial in ovarian cancer with a time-to-event primary endpoint (PFS), but the intervention is non-drug (lifestyle/diet/exercise). Therefore, it does not meet the 'drug-intervention' criterion.待处理
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).Gynecol OncolPMID 36608383无 PMCID2023-Mar0.85The record is an economic evaluation derived from a phase III RCT but does not report direct oncology efficacy outcomes (e.g., survival, progression) required for inclusion in this cohort.待处理
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.Eur J CancerPMID 36641898无 PMCID2023-Mar0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).Eur J CancerPMID 36652891无 PMCID2023-Mar0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).J Gynecol OncolPMID 36659832PMC99958642023-Mar0.85The record is a protocol for a randomized Phase III trial in human endometrial cancer with time-to-event endpoints, but it does not report results and the primary experimental intervention is molecular profile-based radiation therapy, not a specific drug-containing regimen.待处理
Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity.Eur J CancerPMID 36669426无 PMCID2023-Mar0.90The trial is a Phase III randomized study with time-to-event endpoints (DFS, OS) in oncology. However, the abstract does not specify the chemotherapy agent used in the concurrent chemoradiation arm, and the intervention is primarily described as radiation therapy intensification. Without explicit evidence of a specific drug intervention, the 'drug_intervention' criterion is not met.待处理
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 36702138无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.Lancet Diabetes EndocrinolPMID 36738751PMC108511092023-Mar0.98未发现恶性肿瘤人群证据。待处理
Belimumab for the treatment of pediatric patients with lupus nephritis.Expert Opin Biol TherPMID 36750049无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.J UrolPMID 36756959PMC127216552023-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.Br J CancerPMID 36759721PMC100499952023-Mar0.45The record describes a biomarker subgroup analysis of the phase III TRIBE2 randomized trial, reporting OS and PFS outcomes. While it meets the oncology, human, randomized, and phase criteria, and includes relevant survival outcomes, the report is a secondary/subgroup analysis, not the primary or definitive efficacy report of the trial. Eligibility for Kaplan-Meier digitization requires tracing back to the primary trial report, which is not provided here.待处理
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.Lancet OncolPMID 36796394无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.BioDrugsPMID 36802320PMC99711532023-Mar0.95The trial is eligible by most criteria (oncology, human, randomized, phase III, drug intervention, original result). However, it is not eligible because the primary endpoint is a biomarker (percentage change in uNTX/uCr), and the only time-to-event secondary endpoint (time to on-study skeletal-related events) is not a standard efficacy endpoint per the adjudication criteria (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier or HR is reported for a primary/secondary time-to-event efficacy endpoint.待处理
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.Lancet NeurolPMID 36804093无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.Mult SclerPMID 36843446无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Ravulizumab for the treatment of myasthenia gravis.Expert Opin Biol TherPMID 36852670无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.Lancet OncolPMID 36858721无 PMCID2023-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.HIV MedPMID 36912173无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.Clin TherPMID 36922331无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.RMD OpenPMID 36958766PMC100306482023-Mar0.98未发现恶性肿瘤人群证据。待处理
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.Lancet RheumatolPMID 38251609无 PMCID2023-Mar0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.PLoS Negl Trop DisPMID 36888687PMC99946892023-Mar0.98未发现恶性肿瘤人群证据。待处理
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.Alzheimers Res TherPMID 36849969PMC99727562023-Feb-280.98未发现恶性肿瘤人群证据。待处理
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.BMC Res NotesPMID 36849996PMC99708482023-Feb-280.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).BMC MedPMID 36855099PMC99764712023-Feb-280.98未发现恶性肿瘤人群证据。待处理
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.LancetPMID 36774935无 PMCID2023-Feb-250.98未发现恶性肿瘤人群证据。待处理
[Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].Zhonghua Xin Xue Guan Bing Za ZhiPMID 36789598无 PMCID2023-Feb-240.98未发现恶性肿瘤人群证据。待处理
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.BMC Infect DisPMID 36829111PMC99518292023-Feb-240.98未发现恶性肿瘤人群证据。待处理
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.BloodPMID 36322937PMC100237192023-Feb-230.98未发现恶性肿瘤人群证据。待处理
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.N Engl J MedPMID 36795891PMC100641722023-Feb-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理